Collagenase Clostridium Histolyticum Market size is estimated to reach $823.4 million by 2027, growing at a CAGR of 3.1% during the forecast period 2022-2027. Collagenase clostridium histolyticum falls under the category of an enzyme that disassembles collagen. It removes the rigidity caused by thickened tissue in proximal interphalangeal joints. Moreover, it is produced from a species of bacterium named clostridium histolyticum that normally resides in feces. Even though proteins like collagen are beneficial for joint health but their excessive deposition set Dupuytren's contracture and Peyronie's disease in motion. Besides, contracture there are many other fibrotic illnesses associated with organs like skin, liver, and others that are caused by endopeptidases like matrix metalloproteinases. Drinking alcohol, smoking, and diabetes are some common factors that worsen the contracture condition. Therefore, with the growing prevalence of diabetes and smoking trends, the collagenase clostridium histolyticum market's outlook is fairly fascinating. Widescale application of CCH enzymes in the treatment of penile fibrosis and tendons are factors set to drive the growth of the Collagenase Clostridium Histolyticum Market for the period 2022-2027.
Report Coverage
The report: “Collagenase Clostridium Histolyticum Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Collagenase Clostridium Histolyticum Market.
By Disease Type: Cellulite, Penile fibrosis/Peyronie’s disease, Dupuytren’s Contracture, and Others.
By Medicine Type: SANTYL Ointment, and XIAFLEX.
By Form: Powder, and Injection.
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America) and Rest of World (the Middle East and Africa).
Key Takeaways
- Geographically, the North America Collagenase Clostridium Histolyticum Market accounted for the highest revenue share in 2021. It is owing to the higher prevalence of advanced med-tech companies such as Endo International which has been promoting research in the field of the disease type discussed above. However, North America and Europe are poised to dominate the market over the period 2022-2027.
- The innumerable flow of riches in research and development for a more stable and effective cure is said to be the preeminent driver driving the growth of the Collagenase Clostridium Histolyticum Market. Side effects linked with Xiaflex, widespread unemployment ascribing to the COVID-19 has crippled the rising trend of per capita income of nations worldwide and it is said to reduce the market growth.
- Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Collagenase Clostridium Histolyticum Market report.
Collagenase Clostridium Histolyticum Market- Geography (%) for 2021.
For more details on this report - Request for Sample
Collagenase Clostridium Histolyticum Market Segment Analysis-By Disease Type
The Collagenase Clostridium Histolyticum Market based on the disease type can be further segmented into Cellulite, Penile fibrosis/Peyronie's disease, Dupuytren's contracture, and others. Dupuytren's contracture segment held the largest share in 2021. It is a condition in which fibrous connective tissue such as tendons gets thickened and forms knots in palmer fascia. This condition later progressed toward the fingers and cause them to bend. Most of the cases associated with this disease are triggered by genetic deformities. Additionally, a study claims contracture condition gets worse in patients who drink excess alcohol and are afflicted with diabetes. Therefore, with increasing trends of smoking, and alcohol consumption the prevalence of Dupuytren's disease is generally common as compared to penile fibrosis and cellulite. The prevalence of the same increases with age, with the incidence of about 7.2% in males between the age of 45-49 years to 39.5% in 70-74 years old.
Moreover, the same segment dupuytren’s contracture is estimated to be the fastest-growing with a CAGR of 4.2% over the forecast period 2022-2027. This growth is owing to the high frequency of prevalence. Even though with proliferation in injuries associated with accidents and sports the prevalence of penile fibrosis has witnessed a slight increase over the years but it is very unlikely that every time people will injure their genitals.
Collagenase Clostridium Histolyticum Market Segment Analysis-By Form
The Collagenase Clostridium Histolyticum Market based on the form can be further segmented into powder and injection. The injection segment held the largest share in 2021. The growth is owing to far-reaching usage in medical operations related to contracture and Peyronie's disease. Injections are an indispensable part of surgical treatments. Therefore, accruing surgical procedures considering the lack of awareness among a major faction of the population regarding such diseases and not undergoing timely treatments is a prominent factor in the growth of the respective segment. Besides, injections have tons of benefits over orally administered doses like pills and powder. They are proficient in targeting the affected areas and medicine administered through this route absorbs more easily.
However, powder supplements are estimated to be the fastest-growing segment with a CAGR of 4.7% over the forecast period 2022-2027. This growth is owing to elevating consciousness among people with time which is encouraging them to consume powder supplements on daily basis to get rid of severe conditions and are undergoing surgical procedures. Further, the powdered form can be taken without much expertise and can help women suffering from cellulite. Cellulite affects 80-90% of women in Industrial nations.
Collagenase Clostridium Histolyticum Market Segment Analysis-By Geography
The Collagenase Clostridium Histolyticum Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 36% of the overall market in 2021. The growth in this segment is owing to the factors such as the soaring pervasiveness of Penile fibrosis/Peyronie's disease, Dupuytren's contracture. In 2021 the old-age percentage in the U.S. had jumped to 54 million from 46 million in 2020. According to a report, this figure is anticipated to accrue up to 90 million in 2050. Therefore, the growth in the respective segment can be justified by considering the old-age-friendly nature of Dupuytren's illness. Nevertheless, Americans are more open in discussing topics related to sexuality and genitals which makes it easy for them to explain their condition to doctors and undergo required treatment. However, the Europe segment is expected to offer lucrative growth opportunities over the forecast period 2022-2027. This growth is owing to the colossal consumption of alcohol in European nations. Contracture complications have become very common in Northern European countries like Norway, Sweden, Iceland, and others as a study claims that people of Nordic descent are genetically more prone to this illness.
Collagenase Clostridium Histolyticum Market Drivers
Enlarging pervasiveness of contraction problems due to excess alcohol intake and shooting up diabetes compilations is Anticipated to Boost Product Demand.
Besides genetic diabetes hitches, excess smoking and alcohol consumption are major factors that lead to Dupuytren's contracture problems. Therefore, broadening diabetes problems and the rising trend of alcohol intake is driving people one step closer to such complications. No wonder the spread of Dupuytren is so common in Europe because the average per capita alcohol consumption rate of European nations has reached 12 liters. Even people in countries like Moldova consume around 15.2 liters every year. Putting it aside, let's focus on the percentage of the diabetes-afflicted population. A report claims that around 10-10.5 % of adults worldwide had diabetes in 2021. Moreover, the figure is anticipated to reach 12-13% in 2045. All these factors are providing a growth opportunity on a platter to the respective market.
Intensifying injuries and upsurging flows of hard cash in research and development are Expected to Boost Product Demand.
Penile fibrosis, which is commonly known as Peyronie's disease has come to the foreground in recent years. This condition involves the formation of plaque or scar on the penile due to any sports injury or accident and results in reduced or complete loss of pliability. Therefore, the overall usage of collagenase clostridium histolyticum in medications are other treatments associated with this complication have augmented. On another hand, proliferating global spending on healthcare is another big factor driving the growth in the respective market. Last year despite the COVID-19 global health care spending soared by 5.8% in comparison to 2020 and reached 8.8 trillion dollars.
Collagenase Clostridium Histolyticum Market Challenges
Side-effects accompanied by Xiaflex and reduced purchasing capacity of people due to the COVID-19 are Anticipated to Hamper Market Growth.
COVID-19 has derailed the economic growth of almost every country in the world. The budding rates of unemployment are not allowing people from making necessary expenditures as they are left with lower or no means to make a buying which is considered to be a potential setback obstructing the growth of the collagenase clostridium histolyticum market. Additionally, there are many side effects associated with collagenase clostridium medication. Xiaflex administration can set complications such as bleeding, inflammation, redness, cracked skin, and erectile dysfunction in motion. According to the New England Journal of Medicine, a total of 741 injections (444 collagenase and 297 placebo) were administered to 308 patients. Overall, 96.6% of the patients who received collagenase reported at least one treatment-related adverse event, as compared with 21.2% of the patients who received placebo. These factors are impeding the market growth.
Collagenase Clostridium Histolyticum Industry Outlook:
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Collagenase Clostridium Histolyticum Market. Top-10 Collagenase Clostridium Histolyticum companies in this market are-
- Pfizer Inc.
- Healthpoint Ltd.
- Actelion Pharmaceuticals Canada
- Auxilium Pharmaceuticals
- Swedish Orphan Biovitrum
- BioSpecifics Technologies
- Asahi Kasei corporation
- Beijing Solarbio Science & Technology
- Smith & Nephew Plc.
- Advanced Biofactures Corporation
Recent Developments
- In October 2021, Endo International Plc announced its new post-hoc data from phase-3 studies of XIAFLEX (collagens clostridium histolyticum). The product will be actively used in men suffering from Peyronie’s disease. The results were presented in the Sexual Medicine Society of North America. XIAFLEX is composed of two purified collagenases (AUX-I and AUX-II) that hydrolyze collagen under physiologic conditions, resulting in the lysis of collagen deposits. Further, XIAFLEX is the only nonsurgical option available for adult men.
- On December 2, 2020, New York, United States-based biopharmaceutical company “BioSpecifics Technologies Corporation” which produces XIAFLEX announced its successful acquisition by Ireland-based company “Endo International.” Endo deals in specialty pharmaceuticals. The total value of the transactions stands around $658.2 million with $88.50 per share.
- In July 2020, Endo International announced that they have received FDA approval for QWO (collagens clostridium histolyticum). The said would be used in the treatment of moderate to severe cellulite in the buttock of adult women. It became the first-ever injectable treatment for cellulite. When injected into the treatment area, QWO is thought to release the fibrous septae enzymatically by specifically targeting Types 1 and 3 collagen, which may result in smoothing of the skin and an improved appearance of cellulite
Relevant Links:
Musculoskeletal Diseases Market – Forecast (2022 - 2027)
Report Code: HCR 0323
Erectile Dysfunction Drugs Market – Forecast (2022 - 2027)
Report Code: HCR 0908
Generic Drugs Market - Forecast(2022 - 2027)
Report Code: HCR 0217
For more Lifesciences and Healthcare related reports, please click here
